Recombinant Acinetobacter sp. Prolipoprotein diacylglyceryl transferase (lgt)
Description
Introduction to Lipoprotein Diacylglyceryl Transferase in Acinetobacter
Lipoprotein diacylglyceryl transferase (Lgt) is a membrane-bound enzyme that catalyzes the first step in the biogenesis of bacterial lipoproteins, which play crucial roles in bacterial growth, membrane integrity, and pathogenesis . In Gram-negative bacteria, including Acinetobacter species, this enzyme is essential for viability, making it an attractive target for antimicrobial drug development . Lgt recognizes and binds the signal peptide of incoming preprolipoproteins (ppBLPs) and catalyzes the formation of a thioether link between the thiol group on the invariant lipobox cysteine and a diacylglyceryl moiety primarily from phosphatidylglycerol (PG) .
Acinetobacter is a genus of Gram-negative bacteria that includes several clinically important species, particularly A. baumannii, known for causing severe nosocomial infections and exhibiting remarkable resistance to multiple antibiotics. The genome of Acinetobacter sp. K1, a representative strain, has been sequenced and consists of 3,357,632 base pairs organized into 94 contigs with 3,413 protein-coding genes . This genomic information provides a foundation for understanding the genetic basis of Acinetobacter's adaptation mechanisms and the molecular characteristics of its essential proteins, including Lgt.
The recombinant expression of Acinetobacter sp. Lgt allows for detailed biochemical and structural studies of this enzyme, which are crucial for understanding its function and developing specific inhibitors. Unlike many other bacterial enzymes, Lgt inhibition appears to be less susceptible to common resistance mechanisms, enhancing its potential as a novel antibacterial target .
Enzymatic Mechanism and Catalytic Activity
The catalytic mechanism of Lgt involves the transfer of a diacylglyceryl moiety from phosphatidylglycerol to the thiol group of the conserved cysteine residue in the lipobox of preprolipoproteins . This reaction proceeds through several steps: first, the histidine residue in the catalytic site abstracts a proton from the thiol group of the lipobox cysteine, generating a reactive thiolate; this nucleophile then attacks the lipid substrate at the ester bond between the phosphate and diacylglyceryl moiety, resulting in the formation of a prolipoprotein (pBLP) and the release of glycerol phosphate as a by-product .
Interestingly, when phosphatidylglycerol with a racemic glycerol moiety is used as a substrate, Lgt can produce both glycerol-1-phosphate (G1P) and glycerol-3-phosphate (G3P) as products . This feature has been exploited to develop luciferase-coupled assays for measuring Lgt activity in biochemical studies .
Table 1: Key Components of the Lgt Catalytic Reaction
| Component | Function | Notes |
|---|---|---|
| Preprolipoproteins (ppBLP) | Protein substrate | Contains signal peptide with lipobox motif ending in cysteine |
| Phosphatidylglycerol (PG) | Lipid substrate | Provides diacylglyceryl moiety for transfer |
| Catalytic Histidine | Proton abstraction | Essential for generating reactive thiolate |
| Glycerol Phosphate | Reaction by-product | Can be G1P or G3P depending on PG stereochemistry |
| Prolipoprotein (pBLP) | Reaction product | Diacylglyceryl-modified protein anchored to membrane |
Proposed Mechanistic Models
Two distinct mechanistic models have been proposed for how Lgt carries out its diacylglyceryl transferase reaction based on structural and biochemical studies :
-
Preloaded Enzyme Model: In this model, the enzyme is preloaded with two phosphatidylglycerol molecules. The preprolipoproteins substrate docks onto the side cleft near the catalytic histidine, reacts with one of the PG molecules, and the resulting prolipoprotein product undocks into the membrane. The second PG molecule then moves into the space created by the departing prolipoprotein while another PG replaces it from the membrane reservoir .
-
Gated Access Model: This model proposes that a single PG molecule is bound to the enzyme away from the catalytic center, which is blocked by a gate formed by a small loop between the periplasmic ends of transmembrane helices. Interaction with the preprolipoproteins substrate opens the gate, enabling the lipid and the protein substrate to come together at the active site for reaction .
Expression Systems for Recombinant Acinetobacter Lgt
The recombinant expression of Acinetobacter sp. Lgt presents challenges typical of membrane proteins, including difficulties in proper folding, insertion into membranes, and potential toxicity to host cells. While the search results don't specifically detail expression systems for Acinetobacter Lgt, successful recombinant expression of bacterial membrane proteins often employs Escherichia coli-based systems with specialized promoters and fusion tags.
For functional studies of Lgt, expression constructs typically include affinity tags (such as polyhistidine or FLAG tags) for purification purposes, and may incorporate features to enhance protein solubility and membrane integration. The choice of expression host, promoter strength, induction conditions, and purification strategy significantly impacts the yield and activity of the recombinant enzyme.
Biochemical Assays and Activity Measurement
Several complementary approaches have been developed to assess the enzymatic activity of recombinant Lgt. A common method involves measuring the release of glycerol phosphate during the Lgt-catalyzed reaction . Since Lgt can use phosphatidylglycerol with a racemic glycerol moiety, resulting in the release of both G1P and G3P, detection systems have been developed to monitor these by-products. Specifically, G3P detection can be accomplished using a coupled luciferase reaction, providing a sensitive assay for Lgt activity .
Mass spectrometry provides another powerful approach for confirming Lgt activity by detecting the addition of the diacylglyceryl moiety to peptide substrates. This addition corresponds to an increase of 552 Da in the mass of the peptide substrate . Additionally, SDS-PAGE analysis can detect the shift in migration of Lgt-modified peptides, as the diacylglyceryl modification causes the peptide to migrate more slowly through the gel .
Table 2: Methods for Assessing Recombinant Lgt Activity
| Method | Principle | Advantages | Limitations |
|---|---|---|---|
| Glycerol Phosphate Release | Detection of by-product using coupled enzyme assay | Quantitative, amenable to high-throughput | Potential for interference from other enzymes |
| Mass Spectrometry | Detection of 552 Da mass increase in substrate | Direct confirmation of product formation | Requires specialized equipment |
| SDS-PAGE Analysis | Mobility shift of modified peptide | Simple, visual confirmation | Semi-quantitative only |
Substrate Specificity and Kinetic Parameters
Recombinant Lgt enzymes typically exhibit substrate specificity for both the lipid donor and the protein acceptor. On the lipid side, phosphatidylglycerol is the preferred substrate, although other phospholipids may be utilized with lower efficiency. On the protein side, Lgt recognizes a conserved sequence motif called the lipobox, typically [L/V/I]-[A/S/T/G]-[G/A]-C, with the cysteine residue being the site of diacylglyceryl attachment .
In biochemical studies with recombinant Lgt, peptide substrates derived from bacterial lipoproteins, such as the Pal-IAAC peptide (where C is the conserved cysteine), are often used to assess enzymatic activity . The kinetic parameters of the reaction, including Km and kcat values, provide insights into the enzyme's efficiency and can be used to evaluate the effects of mutations or inhibitors on enzyme function.
Lipoprotein Biosynthesis Pathway
In Acinetobacter species, as in other Gram-negative bacteria, bacterial lipoproteins undergo a series of post-translational modifications to become functional membrane-anchored proteins. This process begins with the action of Lgt, which attaches a diacylglyceryl moiety to the conserved cysteine residue in the lipobox of preprolipoproteins, converting them to prolipoproteins .
Following Lgt-mediated diacylglycerylation, the prolipoprotein signal peptidase (LspA) cleaves the signal peptide to the N-terminal side of the lipidated cysteine, generating a diacylated lipoprotein (DA-BLP) . In Gram-negative bacteria like Acinetobacter, a third enzyme, lipoprotein N-acyltransferase (Lnt), then adds a third fatty acyl chain to the N-terminus of the lipoprotein, completing the maturation process .
Table 3: Lipoprotein Biosynthesis Pathway in Acinetobacter and Other Gram-negative Bacteria
| Step | Enzyme | Substrate | Product | Function of Product |
|---|---|---|---|---|
| 1 | Lgt | Preprolipoprotein (ppBLP) | Prolipoprotein (pBLP) | Membrane-anchored via diacylglyceryl moiety and signal peptide |
| 2 | LspA | Prolipoprotein (pBLP) | Diacylated lipoprotein (DA-BLP) | Membrane-anchored via diacylglyceryl moiety only |
| 3 | Lnt | Diacylated lipoprotein (DA-BLP) | Triacylated lipoprotein | Fully mature lipoprotein ready for transport to outer membrane |
Validation as a Druggable Target
Several characteristics make Lgt an attractive target for antibacterial drug discovery. First, it is essential for the viability of Gram-negative bacteria, including Acinetobacter species . Second, its inhibition leads to permeabilization of the outer membrane and increased sensitivity to serum killing and antibiotics, suggesting that Lgt inhibitors might synergize with existing antibiotics . Third, Lgt is a membrane-bound enzyme with a defined active site, making it amenable to structure-based drug design approaches.
The essential nature of Lgt in Gram-negative bacteria was demonstrated through depletion studies in uropathogenic E. coli, which showed that Lgt depletion compromises outer membrane integrity and increases sensitivity to various stressors . Similar effects would be expected in Acinetobacter species given the conserved nature of lipoprotein biosynthesis in Gram-negative bacteria.
Identification of Lgt Inhibitors
Recent research has identified the first Lgt inhibitors that potently inhibit Lgt biochemical activity in vitro and are bactericidal against wild-type Acinetobacter baumannii and E. coli strains . Two compounds, designated G9066 and G2824, have been reported to potently inhibit Lgt biochemical activity and show promising antibacterial properties .
These inhibitors provide valuable chemical starting points for the development of more potent and selective Lgt inhibitors with improved pharmacokinetic properties. Structure-activity relationship studies of these compounds could guide the rational design of next-generation Lgt inhibitors with enhanced efficacy against multidrug-resistant Acinetobacter strains.
Table 4: Characteristics of Identified Lgt Inhibitors
| Compound | Inhibition of Biochemical Activity | Antibacterial Activity | Special Features |
|---|---|---|---|
| G9066 | Potent (low IC50) | Bactericidal against A. baumannii and E. coli | Active against wild-type strains |
| G2824 | Potent (low IC50) | Bactericidal against A. baumannii and E. coli | Active against wild-type strains |
Resistance Mechanisms and Advantages as a Target
Importantly, unlike inhibition of other steps in lipoprotein biosynthesis, deletion of the major outer membrane lipoprotein, lpp, is not sufficient to rescue growth after Lgt depletion or provide resistance to Lgt inhibitors . This suggests that Lgt inhibitors may be less susceptible to this common resistance mechanism, enhancing their potential as antibacterial agents.
This characteristic gives Lgt inhibitors a potential advantage over inhibitors targeting other steps in lipoprotein biosynthesis or transport, such as LspA or the Lol system, where resistance can emerge through alterations in specific lipoproteins. The broader impact of Lgt inhibition on multiple lipoproteins may make it more challenging for bacteria to develop resistance through single mutations or adaptive changes.
Development of Improved Inhibitors
The identification of the first Lgt inhibitors represents a significant milestone, but there is ample room for improvement in terms of potency, selectivity, and drug-like properties. Structure-based design approaches, combined with high-throughput screening of diverse chemical libraries, could yield next-generation inhibitors with enhanced efficacy against multidrug-resistant Acinetobacter strains.
Key considerations for inhibitor development include:
-
Optimizing potency against Acinetobacter Lgt while maintaining activity against other clinically relevant Gram-negative pathogens
-
Enhancing membrane permeability to ensure access to the target enzyme
-
Minimizing potential for resistance development
-
Improving pharmacokinetic properties for potential in vivo applications
Translational Research and Clinical Potential
Translating the promise of Lgt inhibition into clinical applications will require extensive preclinical and clinical development efforts. This includes assessment of efficacy in relevant infection models, toxicology studies, and optimization of drug formulation and delivery.
The potential synergy between Lgt inhibitors and existing antibiotics represents a particularly promising avenue for translation. By compromising outer membrane integrity, Lgt inhibitors might enhance the efficacy of antibiotics that typically struggle to penetrate the Gram-negative cell envelope, potentially revitalizing the use of existing antibiotics against resistant Acinetobacter strains.
Product Specs
Note: We will prioritize shipping the format currently in stock. However, if you have a specific format preference, please indicate it in your order notes. We will fulfill your request whenever possible.
Note: All proteins are shipped with standard blue ice packs. If you require dry ice shipping, please communicate this in advance, as additional fees will apply.
Generally, the shelf life of liquid forms is 6 months at -20°C/-80°C. The shelf life of lyophilized forms is 12 months at -20°C/-80°C.
Target Background
KEGG: aci:ACIAD0518
STRING: 62977.ACIAD0518
Q&A
What is the biochemical function of Lgt in Acinetobacter species?
Lgt catalyzes the first critical step in bacterial lipoprotein biogenesis by transferring a diacylglyceryl moiety from phosphatidylglycerol to the thiol group of a conserved cysteine residue in preprolipoproteins. This reaction creates a thioether bond that is essential for membrane anchoring of bacterial lipoproteins . In Gram-negative bacteria like Acinetobacter, all preprolipoproteins contain a signal peptide followed by a conserved four amino acid sequence ([LVI][ASTVI][GAS]C), known as a lipobox. After secretion through the inner membrane via Sec or Tat pathways, Lgt performs this crucial diacylglyceryl transfer reaction .
The Lgt-catalyzed reaction releases glycerol phosphate as a byproduct, which can be detected experimentally to measure enzymatic activity. This initial lipid modification is followed by signal peptide cleavage by LspA (lipoprotein signal peptidase) and further modification by Lnt (lipoprotein N-acyl transferase) in Gram-negative bacteria, creating mature triacylated lipoproteins .
How does Lgt depletion affect bacterial physiology?
Depletion or inhibition of Lgt in bacteria results in multiple physiological consequences:
-
Permeabilization of the outer membrane, creating vulnerability to external stressors
-
Accumulation of unmodified prolipoprotein forms (UPLP)
-
Disruption of peptidoglycan-lipoprotein linkages
-
Increased sensitivity to serum killing and antibiotics
-
Reduced cation uptake and increased sensitivity to oxidative stress
In S. pneumoniae, an Lgt-deficient mutant shows significantly impaired growth in blood or bronchoalveolar lavage fluid and reduced virulence in infection models . This indicates the crucial role Lgt plays in bacterial survival and pathogenesis beyond simply anchoring lipoproteins.
Why is Acinetobacter sp. Lgt of particular interest to researchers?
Acinetobacter species, particularly A. baumannii, represent important opportunistic pathogens with increasing antibiotic resistance. Lgt inhibitors have demonstrated bactericidal activity against wild-type A. baumannii strains, suggesting therapeutic potential . Unlike inhibition of other steps in lipoprotein biosynthesis, targeting Lgt appears less susceptible to common resistance mechanisms, making it a promising novel antibacterial target for addressing Acinetobacter infections .
What expression systems are optimal for producing recombinant Acinetobacter sp. Lgt?
For recombinant expression of Acinetobacter sp. Lgt, researchers should consider the following:
| Expression System | Advantages | Challenges | Considerations |
|---|---|---|---|
| E. coli-based systems | Well-established protocols, high yield | Potential toxicity, inclusion body formation | Use C41/C43 strains optimized for membrane protein expression |
| Cell-free systems | Avoids toxicity issues, rapid expression | Lower yield, higher cost | Useful for initial characterization studies |
| Homologous expression | Native post-translational modifications | More complex genetic manipulation | Preferred for functional studies |
When expressing Lgt, it's crucial to include appropriate detergents during purification to maintain the native conformation of this membrane-associated enzyme. The purified recombinant enzyme can be validated through biochemical assays measuring glycerol phosphate release, as demonstrated with E. coli Lgt .
How can researchers validate Lgt enzymatic activity in vitro?
A validated method for measuring Lgt activity involves detecting glycerol phosphate release during the transfer of diacylglyceryl from phosphatidylglycerol to a peptide substrate. The search results describe a coupled luciferase reaction detecting both glycerol-1-phosphate (G1P) and glycerol-3-phosphate (G3P) .
Experimental approach:
-
Prepare peptide substrates derived from known lipoproteins (e.g., Pal-IAAC, where C is the conserved cysteine)
-
Incubate purified Lgt with peptide substrate and phosphatidylglycerol
-
Measure released glycerol phosphate through coupled enzymatic reactions
-
Include a negative control using mutated peptide substrate (e.g., Pal-IAA) lacking the critical cysteine
This assay provides a quantitative measure of Lgt activity and can be used to determine inhibition constants (IC50) for potential inhibitors. For example, the inhibitors G9066, G2823, and G2824 demonstrated potent inhibition with IC50 values of 0.24 μM, 0.93 μM, and 0.18 μM, respectively, against E. coli Lgt .
What genetic approaches are useful for studying Lgt function in bacterial systems?
Several genetic techniques have proven effective for investigating Lgt function:
The search results describe successful implementation of CRISPRi to decrease expression of lipoprotein biosynthesis genes, with the level of downregulation consistent with published reports for CRISPRi in bacterial cells . This approach was instrumental in demonstrating that reduced Lgt expression specifically sensitized cells to Lgt inhibitors but not to inhibitors targeting other steps in the pathway.
How does Lgt substrate specificity influence experimental design for inhibitor development?
Lgt must recognize both the phosphatidylglycerol donor and the lipobox motif in preprolipoproteins, presenting two potential sites for inhibitor intervention. Understanding the structural basis of this dual substrate recognition is crucial for rational inhibitor design.
Recent research suggests that inhibitors binding to the conserved phosphatidylglycerol binding site in Lgt might be particularly effective, as mutations disrupting inhibitor binding could compromise essential Lgt function . This hypothesis aligns with observations for other pathway inhibitors like globomycin, which binds to a highly conserved active site and has not generated on-target resistance mutations .
When designing experiments to develop Lgt inhibitors, researchers should:
-
Investigate both substrate binding sites as potential targets
-
Determine if candidate inhibitors competitively inhibit binding of phosphatidylglycerol or prolipoprotein substrates
-
Evaluate the conservation of binding sites across bacterial species to assess potential broad-spectrum activity
-
Consider the structural insights from recent publications on diacylglyceryl modification mechanisms
What distinguishes Lgt inhibition from inhibition of other lipoprotein biosynthesis steps?
A critical finding from the search results is that Lgt inhibition differs fundamentally from inhibition of downstream steps in lipoprotein biosynthesis:
Unlike inhibitors targeting LspA or LolCDE, deletion of the major outer membrane lipoprotein (lpp) does not rescue growth after Lgt depletion or provide resistance to Lgt inhibitors . This suggests that targeting Lgt could overcome a major limitation of other approaches to disrupting lipoprotein biosynthesis, as common resistance mechanisms affecting other pathway inhibitors would be ineffective.
Research has shown that Lpp is actually protective in cells treated with Lgt inhibitors or after Lgt depletion, contrary to expectations based on other pathway inhibitors . This unexpected finding presents an opportunity for developing antibiotics with reduced resistance potential.
How do researchers distinguish between direct and indirect effects of Lgt inhibition?
Distinguishing between direct and indirect effects of Lgt inhibition requires multiple complementary approaches:
-
Biochemical confirmation: Demonstrate that candidate inhibitors directly block Lgt enzymatic activity in vitro using purified components.
-
Phenotypic comparison: Compare phenotypes between chemical inhibition and genetic depletion. The search results describe extensive validation showing that multiple effects observed in Lgt inhibitor-treated cells were recapitulated using lgt inducible deletion strains .
-
Western blot analysis: Monitor accumulation of specific lipoprotein forms. Lgt inhibition leads to accumulation of unmodified pro-Lpp (UPLP), whereas LspA inhibition results in accumulation of diacylglyceryl-modified pro-Lpp (DGPLP) .
-
Genetic sensitization: Use CRISPRi to decrease lgt expression and demonstrate specific sensitization to Lgt inhibitors but not to inhibitors of other pathways .
-
Microscopy: Observe cellular effects like outer membrane blebbing and increased cell size, which are characteristic of Lgt inhibition .
These approaches collectively provide strong evidence for on-target activity of Lgt inhibitors, even when direct resistance mutations cannot be obtained.
How should researchers interpret the absence of on-target resistance mutations to Lgt inhibitors?
The inability to raise on-target resistant mutants to Lgt inhibitors presents an intriguing analytical challenge. Several hypotheses might explain this observation:
-
Essential binding site: If Lgt inhibitors bind to a highly conserved active site essential for function, mutations disrupting inhibitor binding might simultaneously compromise enzymatic activity, resulting in non-viable mutants .
-
Multiple mechanisms of action: Lgt inhibition might affect multiple cellular processes simultaneously, making it difficult for single mutations to confer resistance.
-
Technical limitations: Traditional resistance selection approaches might not be optimal for identifying mutations that confer partial resistance or those requiring specific growth conditions.
For rigorous data interpretation, researchers should:
-
Attempt resistance selection under various conditions
-
Use directed evolution approaches for more sensitive detection of resistance mutations
-
Examine natural variation in Lgt sequences across bacterial species to identify potentially tolerant variants
-
Consider compensatory mutations in other genes that might mitigate Lgt inhibition effects
The search results draw a parallel with globomycin (an LspA inhibitor), which binds a highly conserved active site and for which no on-target resistance mutations have been described , suggesting this might be a characteristic of certain lipoprotein biosynthesis inhibitors.
What statistical approaches are appropriate for analyzing Lgt inhibition data?
When analyzing Lgt inhibition data, researchers should consider:
| Analysis Type | Application | Statistical Considerations |
|---|---|---|
| Dose-response curves | Determine IC50 values | Use non-linear regression, report 95% confidence intervals |
| Time-kill studies | Assess bactericidal activity | Calculate kill rates, compare across strains and conditions |
| Growth curve analysis | Measure growth inhibition | Use area under curve (AUC) for comprehensive comparison |
| Microscopy quantification | Assess morphological changes | Use blinded assessment, quantify multiple parameters |
| Western blot quantification | Measure protein accumulation | Normalize to loading controls, use multiple biological replicates |
Appropriate statistical approaches should include tests for normality, selection of parametric or non-parametric tests based on data distribution, correction for multiple comparisons, and reporting of effect sizes alongside p-values.
How does peptidoglycan-lipoprotein linkage relate to Lgt function?
The search results reveal an unexpected relationship between Lgt function and peptidoglycan-lipoprotein linkage:
These findings suggest that the diacylglyceryl modification by Lgt generates an optimal substrate for the L,D-transpeptidases that covalently link Lpp to peptidoglycan. While both unmodified pro-Lpp (UPLP) and diacylglyceryl-modified pro-Lpp (DGPLP) can be linked to peptidoglycan, the linkage is significantly less efficient in the absence of diacylglyceryl modification .
This mechanistic insight has important implications for antimicrobial development, as it suggests targeting Lgt would overcome the common resistance mechanism (lpp deletion) observed with inhibitors of downstream steps in the lipoprotein biosynthesis pathway .
What techniques are most effective for characterizing Lgt-lipoprotein interactions?
To characterize Lgt-lipoprotein interactions effectively, researchers can employ several complementary techniques:
-
SDS fractionation and Western blot analysis: The search results describe a protocol using SDS fractionation to separate peptidoglycan-associated proteins (PAP) and SDS-soluble non-PAP proteins, followed by Western blot analysis to detect different forms of lipoproteins . This approach successfully identified multiple Lpp forms:
-
Triacylated mature Lpp (fastest migrating)
-
PG-linked Lpp forms
-
Diacylglyceryl-modified pro-Lpp (DGPLP)
-
Unmodified pro-Lpp (UPLP)
-
-
Biochemical assays with purified components: Using synthetic peptide substrates corresponding to lipobox motifs from known lipoproteins to measure Lgt activity in vitro .
-
Microscopy techniques: Fluorescence microscopy can visualize changes in cell morphology (like OM blebbing) associated with Lgt inhibition or depletion .
-
Membrane fractionation: Separate inner and outer membranes to track localization of lipoprotein intermediates during processing.
-
Mass spectrometry: Although not explicitly mentioned in the search results, mass spectrometry would be valuable for detailed characterization of lipid modifications.
How does Lgt inhibition affect bacterial susceptibility to other antimicrobials?
Lgt inhibition or depletion leads to permeabilization of the outer membrane, which has important implications for combination antimicrobial therapy:
-
The disruption of outer membrane integrity through Lgt inhibition increases bacterial sensitivity to serum killing and antibiotics .
-
This membrane permeabilization effect suggests potential synergy between Lgt inhibitors and other antimicrobials, particularly those that typically struggle to penetrate the Gram-negative outer membrane.
-
Unlike some other antimicrobial targets, Lgt inhibition appears less susceptible to common resistance mechanisms, potentially extending the useful lifespan of combination therapies .
Future research should systematically evaluate:
-
Checkerboard assays to quantify synergy between Lgt inhibitors and existing antibiotics
-
Time-kill studies to determine if combination therapy enhances bactericidal activity
-
In vivo efficacy of combination therapy in relevant infection models
-
Resistance development rates when Lgt inhibitors are used alone versus in combination
What are the key considerations for developing Lgt inhibitors as potential therapeutics?
Based on the search results, several factors are critical when developing Lgt inhibitors as potential therapeutics:
The structural characteristics and mechanism of action of successful Lgt inhibitors (like G2823 and G2824) should guide the development of optimized compounds with improved potency, selectivity, and pharmacokinetic properties.
